Zobrazeno 1 - 10
of 6 161
pro vyhledávání: ''
Autor:
Margaret McFarland, Philip Toner, Christopher Nutt, James J. McNamee, Rejina Verghis, Cecilia O'Kane, Kathryn Callaghan, Andrew J. Boyle, Daniel F. McAuley, John Trinder, Paul Johnston
Publikováno v:
Chest. 161:1275-1284
Background There is no pharmacological treatment for the acute respiratory distress syndrome (ARDS). Platelets play an important role in the pathophysiology of ARDS. Pre-clinical, observational and clinically relevant models of ARDS indicate aspirin
Autor:
Antonios Charokopos, Jay H. Ryu, Effrosyni D. Manali, Vasilios Tzilas, Spyridon Papiris, Lykourgos Kolilekas, Demosthenes Bouros
Publikováno v:
Chest. 161:748-752
Autor:
Eitan Kerem, Oded Breuer, Nadia Alyan, Isaiah D. Wexler, Malena Cohen-Cymberknoh, Joel Reiter, David Shoseyov, Shifra Koretz
Publikováno v:
Chest. 161:773-780
Cystic fibrosis is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Novel, highly effective, modulator therapies correcting and potentiating CFTR function are changing the course of the disease. We present a
Autor:
Jennifer Toth, Joel N. Kline, Geoffrey Chupp, Jennifer Trevor, Gerard A. Silvestri, Michel Laviolette, Sundeep Bansal, Richard Tejedor, Nick Kahlstrom, Mark T. Dransfield, Andrew R. Haas, Charlene McEvoy, G. Mark Grubb, Jamie Hey, J. Scott Ferguson, Michael Simoff, Carla Lamb, Edmund McMullen, Momen M. Wahidi, Kyle B. Enfield, Sumita Khatri, Peter LaCamera, J. Mark FitzGerald, Adrian Shifren, Jennifer L. Olson, D. Kyle Hogarth, Mario Castro, Adnan Majid, Marc McClelland
Publikováno v:
Chest. 161:614-628
Background Bronchial thermoplasty is a device-based treatment for subjects ≥18 years with severe asthma poorly controlled with inhaled corticosteroids and long-acting beta-agonists. The Post-FDA Approval Clinical Trial Evaluating Bronchial Thermopl
Autor:
Rohit Gupta, Steven D. Nathan, Oksana A. Shlobin, Jeffrey I. Stewart, Robert P. Baughman, Franck Rahaghi, Elyse E. Lower, Joyce Zeigler, Peter J. Engel
Publikováno v:
Chest. 161:448-457
Background Riociguat is effective in delaying the time to clinical worsening (TCW) in patients with groups 1 and 4 pulmonary hypertension. Research Question Is riociguat more effective than placebo in prolonging TCW in sarcoidosis-associated pulmonar
Autor:
Scott A. Sands, Stefano Vicini, Carolina Lombardi, Gianfranco Parati, Mariapaola Marconi, Ali Azarbarzin, Elisa Perger, Debora Rosa, Lucia Zanotti, Paolo Meriggi, Andrew Wellman, Luigi Taranto Montemurro
Publikováno v:
Chest. 161:237-247
BACKGROUND The recent discovery that a combination of noradrenergic and antimuscarinic drugs improved upper airway muscle function during sleep and reduced OSA severity has revitalized interest in pharmacologic therapies for OSA. RESEARCH QUESTION Wo
Publikováno v:
Chest. 160:2051-2060
People with cystic fibrosis (pwCF) have experienced increased survival and wellbeing in recent decades, such that more than half of those living with CF are adults. Consequently, sexual and reproductive health is increasingly important for pwCF, beca
Autor:
Fuqiang Wen, Fenfen Sun, Dong Luo, Jinping Zheng, Bin Sun, Shisi Zhang, Ye Shen, Qian Zhao, Yong He, Li Li, Binfeng He, Zhen Qin, Kui Wu, Naifu Nie, Paul W. Jones, Xiangyu Ma, Guoqiang Cao, Na-na Zhao, Xingsheng Wang
Publikováno v:
Chest. 160:1660-1669
Background Systemic corticosteroids for the treatment of COPD exacerbations decrease treatment failure and shorten the length of hospitalization. However, the optimal dose is unclear. Research Question Is personalized-dose corticosteroid administered
Publikováno v:
Chest. 160:e523-e526
Case Presentation A 57-year-old man with history of stage IIIB right-sided malignant pleural mesothelioma was admitted from his oncologist’s office for progressive dyspnea of two weeks duration. He had associated dyspnea at rest and a new dry cough
Publikováno v:
Chest. 160:1751-1763
Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are two antifibrotic medications currently approved for slowing the ra